Jazz Pharmaceuticals
JAZZ
230.26
-6.19
-2.62%
Jazz Pharmaceuticals
US · JAZZ
#1123 by market cap
Listed 1970
230.26
-6.19
-2.62%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Citi Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $325Market Newswire · 2026/10/27
-
Company notice
Shanghai Sanyou Medical Co., Ltd: Voluntary Disclosure Notice on the JAZZ System, a spinal fixed connector system, obtained a medical device registration certificateSZSI · 2025/7/16
-
Rating change
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $275 to $319Market Newswire · 2026/11/4
-
Rating change
Barclays Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $271Market Newswire · 2026/10/13
-
Rating change
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $296Market Newswire · 2026/10/8
-
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $308Market Newswire · 2026/11/16
-
Company notice
Jazz Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cook Jennifer E.SEC · 2025/8/12
-
Company notice
Jazz Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(9.5%)SEC · 2024/11/13
-
Company notice
Jazz Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(9.5%)SEC · 2024/10/22
-
Company notice
Jazz Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cook Jennifer E.SEC · 2024/8/7
-
Rating change
Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $314Market Newswire · 2026/10/21
-
Rating change
J.P. Morgan Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $300Market Newswire · 2026/10/28
-
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $330Market Newswire · 2026/11/12
-
Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $324Market Newswire · 2026/11/13
-
UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $337Market Newswire · 2026/10/28
-
Rating change
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $310Market Newswire · 2026/10/16
-
Form 144 | Jazz Pharmaceuticals(JAZZ.US) Director Proposes to Sell 16.24 Million in Common StocksMarket Newswire · 2026/11/7
-
Rating change
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $275 to $325Market Newswire · 2026/11/3
-
Rating change
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Announces Target Price $286Market Newswire · 2026/10/7
-
Rating change
BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $313Market Newswire · 2026/10/9
-
Rating change
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $310Market Newswire · 2026/9/28
-
Rating change
Citi Initiates Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Announces Target Price $325Market Newswire · 2026/9/30
-
Jazz Pharmaceuticals Q3 Adj. EPS $(3.88) Misses $(3.86) Estimate, Sales $1.243B Beat $1.208B EstimateBenzinga · 2026/11/3
-
Rating change
UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $337Market Newswire · 2026/9/14
-
Rating change
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy RatingMarket Newswire · 2026/9/1
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.
Jazz Pharmaceuticals discussion 0 comments